Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide is an investigational synthetic peptide being developed as a once-weekly injectable medication for obesity and related metabolic diseases. It is designed to activate three hormone receptors at the same time, making it different from current GLP-1 medications.
Clinical trials suggest retatrutide may:
Produce substantial weight loss in people with obesity.
Improve blood sugar control in people with type 2 diabetes.
Reduce liver fat.
Improve other markers of metabolic health.
Early trial results have shown average weight loss approaching 30% of body weight in some participants over about two years, though ongoing studies are continuing to evaluate its effectiveness and safety.
Retatrutide is an investigational synthetic peptide being developed as a once-weekly injectable medication for obesity and related metabolic diseases. It is designed to activate three hormone receptors at the same time, making it different from current GLP-1 medications.
Clinical trials suggest retatrutide may:
Produce substantial weight loss in people with obesity.
Improve blood sugar control in people with type 2 diabetes.
Reduce liver fat.
Improve other markers of metabolic health.
Early trial results have shown average weight loss approaching 30% of body weight in some participants over about two years, though ongoing studies are continuing to evaluate its effectiveness and safety.